[1] 刘国仗, 刘力生. 高血压左室肥厚与逆转[J]. 中国循环杂志, 1993, 8(12): 707. [2] Zhou SG, Zhou SF, Huang HQ, et al. Proteomic analysis of hypertrophied myocardial protein patterns in renovascularly hypertensive and spontaneously hypertensive rats[J]. J Proteome Res, 2006, 5(11): 2901-2908. [3] 王建刚, 江凤林, 冯俊, 等. 丹参酮IIA 对血管紧张素Ⅱ诱导的心肌细胞肥大与凋亡干预的研究[J]. 中国现代医学杂志, 2007, 17(18): 2202-2204. [4] 孙联平, 郑智. 丹参酮ⅡA 对肥厚心肌细胞核因子-κB 的影响[J]. 实用老年医学, 2004, 18(1): 25-27. [5] Bi HC, Law FC, Zhong GP, et al. Study of tanshinone IIA tissue distribution in rat by liquid chromatography-tandem mass spectrometry method[J]. Biomed Chromatogr, 2007, 21(5): 473-479. [6] Bishop JE, Kiernan LA, Montgomery HE, et al. Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m (Ren2) 27 rats[J]. Cardiovasc Res, 2000, 47(1): 57-67. [7] Mori A, Saito M, Sakamoto K, et al. Stimulation of prostanoid IP and EP(2) receptors dilates retinal arterioles and increases retinal and choroidal blood flow in rats[J]. Eur J Pharmacol, 2007, 570(1-3): 135-141. [8] Habig WH, Pabst MJ, Jakoby WB. The first enzymatic step in mercapturic acid formation[J]. J Biol Chem, 1974, 249(22): 7130-7139. [9] Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms[J]. Hypertension, 2003, 42(6): 1075-1081. [10] Yamamoto E, Lai ZF, Yamashita T, et al. Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis[J]. J Hypertens, 2006, 24(10): 2057-2069. [11] Minhas KM, Saraiva RM, Schuleri KH, et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy[J]. Circ Res, 2006, 98(2): 271-279. [12] Tang W, Eisenbrand G, Salvia Bge. Chinese drugs of plant origin[M]. Berlin Heidelberg, Germany: Springer, 1992:891-902. [13] Fu J, Huang H, Liu J, et al. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis[J]. Eur J Pharmacol, 2007, 568:213-221. [14] Loch D, Levick S, Hoey A, et al. Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affectingblood pressure in DOCA-salt hypertensive rats[J]. J Cardiovasc Pharmacol, 2006, 47(3): 396-404. [15] Bosch TM, Meijerman I, Beijnen JH, et al. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer[J]. Clin Pharmacokinet, 2006, 45(3): 253-285. [16] Cnubben N, Rietjens I, Wortelboer H, et al. The interplay of glutathione-related processes in antioxidant defense[J]. Environ Toxicol Pharmacol, 2001, 10(4): 141-152. |